12 completed, 10 unknown, 4 recruiting, 3 not yet recruiting. 32 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 32 | Completed 12, Unknown 10, Recruiting 4, Not yet recruiting 3, Active not recruiting 1, Terminated 1, Withdrawn 1 |
Follow Glomerulonephritis, IGA: new trials by email Literature Review of Glomerulonephritis, IGA trials Research Report on Glomerulonephritis, IGA
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Obinutuzumab Beta in Primary IgA Nephropathy With Active Pathological Lesions Obinutuzumab Beta - Primary IgA Nephropathy | Phase 4 | Not yet recruiting | Ruijin Hospital | 20 | 2026-12-10 | 2026-10-22 |
| Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN) atrasentan - IgA Nephropathy (IgAN), Immunoglobulin A Nephropathy (IgAN) | Phase 4 | Not yet recruiting | University of Illinois at Chicago | 20 | 2026-09-29 | 2026-09-21 |
| Efficacy and Safety of Nefecon on Prevention of Relapse of IgA Nephropathy NEFECON, Placebo - IgA Nephropathy (IgAN) | Phase 4 | Recruiting | Nanfang Hospital, Southern Medical University | 288 | 2026-06-23 | 2026-09-02 |
| Nefecon and Ambrisentan in IgA Nephropathy "Nefecon®","Ambrisentan" - IgA Nephropathy, Chronic Kidney Disease | Phase 4 | Recruiting | The First Hospital of Jilin University | 129 | 2025-09-01 | 2025-09-15 |
| Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy? Oral prednisolone and SoC, Gut-directed budesonide and SoC, Mycophenolate mofetil (MMF) and SoC - IgA Nephropathy, Renal Insufficiency, Chronic | Phase 4 | Recruiting | Christian Medical College, Vellore, India | 585 | 2025-02-15 | 2025-07-14 |
| Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy TARPEYO® - IgA Nephropathy | Phase 4 | Active not recruiting | Calliditas Therapeutics AB | 60 | 2024-12-17 | 2026-09-24 |
| Efficacy and Safety of Probiotics Combined With Enteric-coated Budesonide Capsules in Patients With Primary IgA Nephropathy probiotics combined with enteric-coated budesonide capsule, probiotics placebo combined with enteric-coated budesonide capsules - Glomerulonephritis, IGA, Probiotics | Phase 4 | Not yet recruiting | Gang Xu | 206 | 2024-07-01 | 2024-07-30 |
| Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy. Corticosteroid, Renin-angiotensin sytem blockers, Sodium-glucose cotransporter 2 inhibitor - Glomerulonephritis, Immunoglobulin A Nephropathy | Phase 4 | Recruiting | Fondazione Schena | 878 | 2023-05-01 | 2025-04-02 |
| Rituximab and RASi in Patients with IgAN Rituximab, RAS 2410 - IgA Nephropathy | Phase 4 | Completed | Nan Chen,MD | 116 | 2020-07-01 | 2025-03-14 |
| A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy rituximab group - IgA Nephropathy | Phase 4 | Unknown | XIEJINGYUAN | 116 | 2020-06-20 | 2023-04-21 |
| Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency Leflunomide 20 mg+prednisone 0.5mg/kg/d - Glomerulonephritis, IGA, Renal Insufficiency, Chronic | Phase 4 | Unknown | Shenzhen Second People's Hospital | 70 | 2019-09-12 | 2020-02-18 |
| Effect of Immunosuppression in IgA Nephropathy Immunosuppressive treatment, intensive supportive care - Biopsy-proven IgA Nephropathy | Phase 4 | Unknown | Yonsei University | 174 | 2019-03-01 | 2019-02-08 |
| Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy prednisone and cyclophosphamide, prednisone alone - IgA Nephropathy | Phase 4 | Unknown | Guangdong Provincial People's Hospital | 133 | 2016-12-01 | 2017-07-17 |
| Hydroxychloroquine Sulfate Alleviates Persistent Proteinuria in IgA Nephropathy Hydroxychloroquine Sulfate, Valsartan - Primary IgA Nephropathy | Phase 4 | Unknown | Peking Union Medical College Hospital | 98 | 2016-06-01 | 2017-09-20 |
| Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy Mycophenolate Mofetil, ACE inhibitor, Corticosteroid - IgA Nephropathy | Phase 4 | Unknown | Yonsei University | 100 | 2016-06-01 | 2016-12-05 |
| Acthar on Proteinuria in IgA Nephropathy Patients Acthar 80 unit injection - IgA Nephropathy, Proteinuria | Phase 4 | Withdrawn | Baylor College of Medicine | 2015-02-01 | 2017-04-05 | |
| Hydroxychloroquine Sulfate for Reduction of Proteinuria in Patients With IgA Nephropathy: a Self- Controlled Study Hydroxychloroquine Sulfate - Primary IgA Nephropathy | Phase 4 | Completed | LLiu | 20 | 2015-01-01 | 2015-12-17 |
| Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy Losartan, Abelmoschus manihot - IgA Nephropathy | Phase 4 | Unknown | Chen Xiangmei | 1600 | 2014-09-01 | 2016-07-06 |
| Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy prednisone plus cyclophosphamide, Prednisone alone - IgA Nephropathy | Phase 4 | Unknown | Guangdong Provincial People's Hospital | 135 | 2012-12-01 | 2017-07-14 |
| Rituximab in Recurrent IgA Nephropathy Intravenous Rituximab, ACEI/ARB and corticosteroids - Recurrent IgA Nephropathy | Phase 4 | Unknown | Chulalongkorn University | 30 | 2012-01-01 | 2015-10-08 |
Showing 20 of 32. Sign in to see all of them.
Proteinuria (12) · Glomerulonephritis (5) · Renal Insufficiency, Chronic (5) · Glomerulonephritis, Membranous (2) · Glomerulosclerosis, Focal Segmental (2) · Kidney Failure, Chronic (2) · Albuminuria (1) · Autoimmune Diseases (1) · Camurati-Engelmann Syndrome (1) · Diabetic Nephropathies (1) · Fibrosis (1) · Hypertension (1) · IgA Vasculitis (1) · Immune System Diseases (1)
Female Urogenital Diseases (32) · Female Urogenital Diseases and Pregnancy Complications (32) · Male Urogenital Diseases (32) · Urogenital Diseases (32) · Autoimmune Diseases (31) · Immune System Diseases (31) · Kidney Diseases (31) · Nephritis (31) · Urologic Diseases (31) · Glomerulonephritis (27) · Pathological Conditions, Signs and Symptoms (17) · Signs and Symptoms (14) · Urination Disorders (13) · Urological Manifestations (13) · Pathologic Processes (8)
Prednisolone (4) · Adrenal Cortex Hormones (3) · Hydroxychloroquine (3) · Losartan (3) · Mycophenolic Acid (3) · Prednisone (3) · Rituximab (3) · Valsartan (3) · aliskiren (3) · Angiotensin-Converting Enzyme Inhibitors (2) · Cyclophosphamide (2) · Methylprednisolone Hemisuccinate (2) · Ramipril (2) · Adenosine Triphosphate (1) · Angiotensin Receptor Antagonists (1)
Guangdong Provincial People's Hospital (3) · Columbia University (2) · The University of Hong Kong (2) · Yonsei University (2) · A. Manzoni Hospital (1) · Baylor College of Medicine (1) · Calliditas Therapeutics AB (1) · Chen Xiangmei (1) · Chinese University of Hong Kong (1) · Christian Medical College, Vellore, India (1) · Chulalongkorn University (1) · Fondazione Schena (1) · Gang Xu (1) · Hospital Britanico (1) · Kagawa University (1)
China (15) · United States (7) · Italy (3) · South Korea (2) · Argentina (1) · Hong Kong (1) · India (1) · Japan (1) · Puerto Rico (1) · Switzerland (1) · Thailand (1)
Anand Srivastava, MD, MPH (1) · Antonello Pani, MD (1) · Cheuk-Chun Szeto, MD (1) · Choli Hartono, MD (1) · Claudio Ponticelli, MD (1) · Claudio Pozzi, MD (1) · David Sheikh-Hamad, MD (1) · Fernando C. Fervenza, M.D. (1) · Francesco Locatelli, MD (1) · Francesco P Schena (1) · George T John, DM, FRCP, FRACP (1) · Gerald B Appel, MD (1) · Gian B Fogazzi, MD (1)
PMID 38299639, PMID 26032537, PMID 26630142, PMID 28763548, PMID 10093981, PMID 15851648, PMID 16014059, PMID 17533019, PMID 17978307, PMID 18436082, PMID 18930568, PMID 19571790, PMID 19571791, PMID 19628647, PMID 21606384, PMID 21680850, PMID 21852672, PMID 22075320, PMID 22722778, PMID 22995802, PMID 24009220, PMID 24029421, PMID 24191893, PMID 24641955, PMID 25018935, PMID 25585823, PMID 25677392, PMID 27821627, PMID 28341274, PMID 28395659, PMID 29988921, PMID 30177015, PMID 32409237, PMID 32889014, PMID 32970396, PMID 32998816, PMID 33023926, PMID 37772889, PMID 38770818, PMID 38864363, PMID 9100040